Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Health & Fitness
Sports
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Podjoint Logo
US
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/d0/19/e7/d019e72f-05f2-8d1d-bd8e-a211c71aae72/mza_14299790810783861641.jpg/600x600bb.jpg
NECTA Annual Drug Development Meeting
NECTA
7 episodes
4 days ago
Each year the NSW Early Phase Clinical Trials Alliance (NECTA) hosts the international Drug Development Meeting. Join us in listening to world-renowned speakers dive into topics across oncological therapy development, from trial design to the emerging use of AI.
Show more...
Medicine
Health & Fitness
RSS
All content for NECTA Annual Drug Development Meeting is the property of NECTA and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Each year the NSW Early Phase Clinical Trials Alliance (NECTA) hosts the international Drug Development Meeting. Join us in listening to world-renowned speakers dive into topics across oncological therapy development, from trial design to the emerging use of AI.
Show more...
Medicine
Health & Fitness
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/40933329/40933329-1712547350131-8c00bb869ff44.jpg
Dose Ranging and Optimisation in Oncology: Implications for the Design and Conduct of Early Clinical Trials
NECTA Annual Drug Development Meeting
53 minutes 33 seconds
1 year ago
Dose Ranging and Optimisation in Oncology: Implications for the Design and Conduct of Early Clinical Trials

Speaker: Prof Lesley Seymour, Queens University Kingston Ontario - Session 3, Talk 2

NECTA Annual Drug Development Meeting
Each year the NSW Early Phase Clinical Trials Alliance (NECTA) hosts the international Drug Development Meeting. Join us in listening to world-renowned speakers dive into topics across oncological therapy development, from trial design to the emerging use of AI.